The Brazilian National Sanitary Surveillance Agency (Anvisa), linked to the Ministry of Health of Brazil, announced this Wednesday the death of a volunteer participating in clinical trials of the COVID-19 vaccine of the pharmaceutical company AstraZeneca and the University of Oxford in the South American country.

Oxford confirmed the plan continue with rehearsals and added that, after careful evaluation, “there is no concern about the security of the tests,” according to the agency. Reuters. For its part, the Brazilian newspaper O Globe, citing unidentified sources, reported that the volunteer had been given a placebo and not the vaccine.

Anvisa has not provided further details, for which it has alluded to the confidentiality of medical data of the trial participants. Also AstraZeneca has declined to demonstrate at the moment.

“According to the national and international regulations of Good Clinical Practices, the data on volunteers from clinical research must be kept secret, in accordance with the principles of confidentiality, human dignity and protection of the participants “, Anvisa stressed.

Has been the University of Sao Paulo, which is helping to coordinate phase 3 of the tests in the country, who has communicated that the volunteer was Brazilian, without revealing the exact place of residence of the deceased. CNN Brazil reported for his part that the volunteer was a 28 year old man of age resident in Rio de Janeiro.

This same Wednesday there controversy in Brazil over the acquisition of vaccines, after the president, Jair Bolsonaro, announced on his social networks that the Government will not buy the Sinovac vaccine, despite the fact that his Health Minister, Army General Eduardo Pazuello, signed a protocol of intentions the day before to acquire 46 millions of doses of such an immunizer worth 427 million dollars.

As a result of this statement by Bolsonaro, different Brazilian sectors have asked him not to turn the acquisition of the coronavirus vaccine into a new electoral and ideological dispute.